



Sequella, Inc.  
9610 Medical Center Drive  
Rockville, MD 20850  
Tele: 301-762-7776  
[www.sequella.com](http://www.sequella.com)

**NEWS RELEASE**

**March 28, 2007**

## **DR. CAROL NACY RECEIVES CLINICAL TRIALS AWARD AT WOMEN IN BIO'S 5<sup>TH</sup> ANNUAL ENTREPRENEUR DINNER**

WASHINGTON, DC – Women In BIO honored Sequella CEO, Dr. Carol Nacy, at their 5<sup>th</sup> annual Entrepreneur Dinner at the National Press Club on Tuesday, March 27, 2007. Dr. Nacy, a founder of Sequella, a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential, received a “Special Outstanding Achievement Award for Clinical Trials,” since Sequella has both a new TB drug, SQ 109 in Phase I human clinical trials in the United States and a new early detection diagnostic, the TB Patch, in international clinical trials. Five “Special Outstanding Achievement Awards” in various categories were awarded as part of the WIB 5<sup>th</sup> anniversary celebration.

Women In Bio is a national membership organization committed to helping women build sustainable bioscience companies. WIB provides educational programs for entrepreneurs and executives, networking opportunities, and access to resources to achieve success. The mission of WIB is to support all women involved in the bio industry by providing professional development workshops to enhance their skills for career advancement. In 2002, its founding year, WIB recognized 23 women Founders of biotech and life science companies; in 2007, 63 women entrepreneurs were recognized.

“Dr. Carol Nacy personifies what it is to be a woman entrepreneur in the field of biotechnology,” said Robbie Melton, President of Women In Bio. “She has had a distinguished career, having worked as a scientist at Walter Reed Army Institute of Research before joining EntreMed, a privately held company that went public during her tenure, to today, as leader of an 18-person company. Through her leadership, Sequella has received FDA Fast-track status for its lead therapeutic compound and has raised more than \$25 million in funding from peer-reviewed competitive grants and high net worth investors. We are very proud of her accomplishments and believe this award to be especially fitting.”

In addition to Dr. Nacy’s award, Women In BIO honored Dr. Kay Wagoner, CEO of Icagen, Inc. for equity capital raised; Dr. Judith Britz, CEO of Cylex, Inc. received the Outstanding Achievement Award for products developed; Dr. Sau Lan Tang Staats, CEO of Phoenix S&T, Inc. received an Outstanding Achievement Award for revenue growth; and Dr. Sherri Bale, CEO of Gene DX received an Outstanding Achievement Award for company employment growth.

###

MEDIA CONTACT: Alicia Moran 703-739-2424 x 110 or [Alicia@brightlinemedia.com](mailto:Alicia@brightlinemedia.com)

---

---